According to the phase 3 trial data, individuals who have never had dengue before will receive 80% protection from the single-dose tetravalent Butantan-Dengue vaccine, whereas those who have previously had dengue will receive 89% protection.

The phase 3 trial began in February of 2016 and included 16,235 participants in Brazil; roughly 10,000 were vaccinated with the one-dose vaccine, and about 6,000 received a placebo.

As of now, the World Health Organisation has approved and recommended the use of two further dengue vaccines: TAK-003 (2 doses) and Dengvaxia (3 doses).

However, dengue-naive recipients may experience antibody-dependent enhancement if they receive a vaccine before a natural infection.

Dengvaxia is only advised for use in individuals aged 9 to 45 who have at least one recorded case of dengue.